MARKET

IMNM

IMNM

Immunome Inc
NASDAQ
24.39
+0.49
+2.05%
After Hours: 24.39 0 0.00% 18:30 07/07 EDT
OPEN
24.00
PREV CLOSE
23.90
HIGH
25.00
LOW
23.14
VOLUME
1.56M
TURNOVER
--
52 WEEK HIGH
27.65
52 WEEK LOW
7.96
MARKET CAP
2.76B
P/E (TTM)
-10.3164
1D
5D
1M
3M
1Y
5Y
1D
Immunome grants 344,000 inducement stock options priced at $21.49 per share
PUBT · 8h ago
IMMUNOME REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 8h ago
Weekly Report: what happened at IMNM last week (0629-0703)?
Weekly Report · 1d ago
Immunome director Isaac Barchas disposes of 201,050 common shares worth $4.4 million
PUBT · 5d ago
Analyst Brian Cheng Initiates Buy on Immunome, Citing Differentiated Pipeline and Compelling Risk‑Reward Profile
TipRanks · 06/30 10:15
Immunome Chief Medical Officer Robert Lechleider disposes of 55,000 common shares worth $1.09 million
PUBT · 06/29 20:53
Weekly Report: what happened at IMNM last week (0622-0626)?
Weekly Report · 06/29 09:43
Weekly Report: what happened at IMNM last week (0615-0619)?
Weekly Report · 06/22 09:48
More
About IMNM
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.

Webull offers Immunome Inc stock information, including NASDAQ: IMNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMNM stock methods without spending real money on the virtual paper trading platform.